IRCT20221126056613N2 IRCT 2023-03-27 Oroumia University of Medical Sciences Comparing the effect of combined intrathecal dexamethasone-bupivacaine with bupivacaine Comparing the effect of combined intrathecal dexamethasone-bupivacaine with bupivacaine alone for spinal anesthesia in a cesarean section 2023-03-04 anticipated 50 Complete https://irct.ir/trial/68965 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients, using random allocation software, were randomly divided into median and paramedian groups. By selecting the simple randomization method in the randomization box and entering the determined total sample size in this software, numbers were given to the patients and the patients were allocated into two groups according to computer-generated numbers, Blinding description: The patients and the nurse who cares for participants during the trial will be blinded by the intervention and control groups. Written consent is obtained from patients, but at the same time, patients do not know whether they are in the placebo or intervention group. 3 Duration of spinal analgesia. Intervention 1: Intervention group: Spinal anesthesia was performed in the sitting position at L4 -L5 level through a midline approach using a 25-gauge Quincke spinal needle. The patients of the intervention group received 12 mg of 0.5% hyperbaric bupivacaine and 8 mg preservative-free dexamethasone with the Dexadic brand name (2 ml), overall 5 ml volume intrathecally. The drug was made available to the researchers of this project by Caspin Pharmaceutical Company. Intervention 2: Control group: Spinal anesthesia was performed in the sitting position at L4 -L5 level through a midline approach using a 25-gauge Quincke spinal needle. The control group received 12 mg of 0.5% hyperbaric bupivacaine diluted in preservative-free normal saline (2 ml) with the same appearance as dexamethasone. The drug was made available to the researchers of this project by Caspin Pharmaceutical Company. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is -